Jodi Antonelli

Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in 2030

BACKGROUND The prevalence of urolithiasis and its risk factors such as obesity and diabetes have increased over time. OBJECTIVE Determine the future cost and prevalence of kidney stones using current and projected estimates for stones, obesity, diabetes, and population rates. DESIGN, SETTING, AND PARTICIPANTS The stone prevalence in 2000 was estimated from the National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 2007-2010. The cost per percentage prevalence of stones in 2000, calculated using Urologic Diseases in America Project data, was used to estimate the annual cost of stones in 2030, adjusting for inflation and increases in population, stone prevalence, obesity and diabetes rates. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The primary outcome was prevalence and cost of stones in 2030. The secondary outcomes were the impact of obesity and diabetes on these values, calculated using odds ratios for stones by body mass index and diabetes status. RESULTS AND LIMITATIONS The annual cost of stone disease in 2000, adjusted for inflation to 2014 US dollars, was approximately

Exercise therapy across the prostate cancer continuum

2.81 billion. After accounting for increases in population and stone prevalence from 2000, the estimated cost of stones in 2007 in 2014 US dollars was

Prostate-specific antigen screening among young men in the United States

3.79 billion. Future population growth alone would increase the cost of stone disease by

Resveratrol Worsens Survival in SCID Mice With Prostate Cancer Xenografts in a Cell-Line Specific Manner, Through Paradoxical Effects on Oncogenic Pathways

780 million in 2030. Based on projected estimates for 2030, obesity will independently increase stone prevalence by 0.36%, with an annual cost increase of

Association of Cigarette Smoking With Interval to Biochemical Recurrence After Radical Prostatectomy: Results from the SEARCH Database

157 million. Diabetes will independently increase stone prevalence by 0.72%, associated with a cost increase of

Effect of intermittent fasting on prostate cancer tumor growth in a mouse model

308 million annually by 2030. NHANES data, however, capture patient self-assessment rather than medical diagnosis, which is a potential bias. CONCLUSIONS The rising prevalence of obesity and diabetes, together with population growth, is projected to contribute to dramatic increases in the cost of urolithiasis, with an additional

Advances in percutaneous nephrolithotomy.

1.24 billion/yr estimated by 2030. PATIENT SUMMARY Obesity, diabetes, and population rates will contribute to an estimated

Laparoscopic radiofrequency ablation of small renal tumors: long-term oncologic outcomes.

1.24 billion/yr increase in the cost of kidney stones by 2030.

A prospective, multi-institutional study of flexible ureteroscopy for proximal ureteral stones smaller than 2 cm

Exercise has been increasingly investigated as an adjunct therapy for cancer patients. The purpose of this paper is to comprehensively review the literature regarding exercise as a therapeutic adjunct for prostate cancer (PC). Several studies in patients with PC have shown quality of life improvements associated with exercise. Although no study has established the effect of exercise as a monotherapy for PC, the molecular mechanisms responsible for the potential association between exercise and PC are being elucidated. Given the low-risk, high-reward nature of these studies, further investigations are needed to better define the function of exercise along the PC continuum.

Low-Carbohydrate Diets and Prostate Cancer: How Low Is "Low Enough"?

Disagreement exists on the use of prostate‐specific antigen (PSA) tests for cancer‐risk stratification in young men in the United States. Little is known about the use of PSA testing in these men. To understand policy implications of risk stratification, the authors sought to characterize PSA use among young men.